Across TCGA pan-cancer cohorts, LCE5A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LCE5A data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LCE5A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LCE5A expression acts as an unfavorable survival marker.

BLCA, LUAD, and SCLC are the cancer types where LCE5A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	36	view →
LUAD	OS	Median	All	0.090	0.788	<.001	18	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LCE5A tumor-vs-normal RNA expression · all LCE5A data types